

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT8022443

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
EURO-CELTIQUE S.A.	12/10/2019
RECEIVING PARTY DATA	
Name:	PURDUE PHARMA L.P.
Street Address:	ONE STAMFORD FORUM
Internal Address:	201 TRESSER BLVD.
City:	STAMFORD
State/Country:	CONNECTICUT
Postal Code:	06901
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	17730276
CORRESPONDENCE DATA	
Fax Number:	(617)607-9200
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	(617) 449-6523
Email:	kkantorski@mccarter.com
Correspondent Name:	MCCARTER & ENGLISH, LLP
Address Line 1:	265 FRANKLIN STREET
Address Line 4:	BOSTON, MASSACHUSETTS 02110
ATTORNEY DOCKET NUMBER:	132179-00602
NAME OF SUBMITTER:	THAO NGUYEN, PH.D.
SIGNATURE:	/Thao Nguyen/
DATE SIGNED:	06/23/2023
Total Attachments: 5	
source=Executed Parent Assignment (Euro-Celtique to PPLP)#page1.tif	
source=Executed Parent Assignment (Euro-Celtique to PPLP)#page2.tif	
source=Executed Parent Assignment (Euro-Celtique to PPLP)#page3.tif	
source=Executed Parent Assignment (Euro-Celtique to PPLP)#page4.tif	
source=Executed Parent Assignment (Euro-Celtique to PPLP)#page5.tif	

PATENT ASSIGNMENT AGREEMENT

THIS PATENT ASSIGNMENT AGREEMENT (this "Assignment"), effective as of December 10, 2019 (the "Effective Date"), is by and between **EURO-CELTIQUE S.A.**, a Luxembourg company with its registered office at 1, rue Jean Piret, 2350 Luxembourg, Luxembourg ("Assignor") and **PURDUE PHARMA L.P.**, a Delaware limited partnership whose principal place of business is at One Stamford Forum, 201 Tresser Boulevard, Stamford, Connecticut 06901, United States ("Assignee"). Each of Assignor and Assignee may be individually referred to herein as a "Party" and collectively as the "Parties".

WITNESSETH:

WHEREAS, Assignor desires to assign, transfer, convey and deliver to Assignee all of its right, title and interest in and to the Assigned Patent Rights (as defined below) in the Territory and Assignee desires to acquire all such right, title and interest.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties, intending to be legally bound, hereby agree as follows:

1. Definitions. As used in this Assignment, the following terms have the following meanings:

a. "Assigned Patent Rights" means (i) the patents and patent applications set forth on Schedule 1, (ii) any and all divisionals, continuations, continuations-in-part, reissues, extensions, reexaminations and equivalents of any of the foregoing in the Territory, (iii) the right to claim priority in the Territory to any of the foregoing (including the right to claim priority in the Territory to any patents or patent applications to which any of the foregoing claim priority) and to prosecute and obtain the grant of any patent from any of the foregoing in the Territory, and (iv) any and all rights in the Territory in the inventions disclosed in any of the foregoing.

b. "Territory" means the United States of America, its districts, territories, possessions and commonwealths, including the Commonwealth of Puerto Rico.

2. Assignment. Assignor hereby irrevocably assigns, transfers, conveys and delivers to Assignee (i) all of its right, title and interest in, to and under all Assigned Patent Rights in the Territory, together with all goodwill in the Territory associated with the foregoing, in each case to be held and enjoyed by Assignee as fully and entirely as the same would have been held and enjoyed by Assignor if this assignment had not been made, (ii) all rights to sue, claim and recover for past, present and future infringement, misappropriation, dilution or other violation of any Assigned Patent Rights in the Territory, and (iii) all income, royalties, damages and payments now or hereafter due or payable with respect to any of the foregoing.

3. Further Assurances; Power of Attorney. Assignor shall, upon the reasonable request by Assignee, execute all other documents and take all actions as may be necessary or desirable to enable Assignee to prosecute, perfect, enforce, defend, register and/or record its right, title and interest in, to and under the Assigned Patent Rights, in each case, without further compensation but at the expense of Assignee. In the event that Assignor fails to execute any such document or take any such action as set forth in the preceding sentence, Assignor hereby designates Assignee as Assignor's agent, and hereby grants to Assignee a power of attorney with full power of substitution, which power of attorney shall be deemed coupled with an interest, for the purpose of executing such documents or taking such actions.

4. Authorization to Record. Assignor hereby authorizes and requests the officials of the United States Patent and Trademark Office to record and register Assignee as assignee and owner of all right, title and interest in, to and under the Assigned Patent Rights. Assignor hereby authorizes and requests the Commissioner of Patents and Trademarks and any other granting authority in the Territory to issue any Letters Patent resulting from any of the Assigned Patent Rights to Assignee.

5. Governing Law; Successors and Assigns. This Assignment shall be governed by, and construed in accordance with, the laws of the State of New York without regard to the choice of law principles thereof. This Assignment is binding upon, and inures to the benefit of, the Parties and their respective successors and assigns.

6. Amendments and Waivers. Any provision of this Assignment may be amended or waived if, but only if, such amendment or waiver is in writing and is signed, in the case of an amendment, by each Party, or in the case of a waiver, by the Party against whom the waiver is to be effective. No failure or delay by either Party in exercising any right, power or privilege hereunder shall operate as a waiver thereof nor shall any single or partial exercise thereof preclude any other or further exercise thereof or the exercise of any other right, power or privilege.

7. Counterparts. This Assignment may be signed in any number of counterparts, each of which shall be an original, with the same effect as if the signatures thereto and hereto were upon the same instrument. A signed copy of this Assignment delivered by facsimile, e-mail or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Assignment.

[SIGNATURE PAGE FOLLOWS]


PURDUE PHARMA L.P.
 By: Purdue Pharma Inc., its general partner

By: Philip C. Strassburger
 Name: Philip C. Strassburger

Title: Sr. Vice President, IP Strategy & Litigation

STATE OF Connecticut,
 COUNTY OF Fairfield)^{ss}

On the 10th day of DECEMBER 2019 before me personally came Philip C. Strassburger who is personally known to me on the basis of satisfactory evidence to be the individual whose name is subscribed to the within instrument and did depose and say to me that he or she executed the same in his or her capacity as Sr. VP Strat. & Lit. of Purdue Pharma L.P. the entity described in and which executed the foregoing instrument, and that he or she executed and delivered said instrument pursuant to authority given by the board of directors of such entity (or other applicable authority of such entity).



Emily P. Casinelli
 Notary Public

(PLACE STAMP AND SEAL ABOVE)

Schedule 1**ASSIGNED PATENT RIGHTS**

Patent Application No.	Filing Date	Title	Designated States
PCT/EP2018/065662	Jun. 13, 2017	Compounds For Treating TNBC	US only
PCT/EP2018/065664	Jun. 13, 2017	Tinostamustine For Use In The Treatment Of T-Cell Prolymphocytic Leukaemia	US only
PCT/EP2018/065668	Jun. 13, 2017	Tinostamustine For Use In Treating Sarcoma	US only
PCT/EP2018/065669	Jun. 13, 2017	Tinostamustine For Use In Treating Ovarian Cancer	US only
PCT/IB2018/0593818	Nov. 26, 2018	Humanized Antibodies Targeting Human Tissue Factor	US only